Nothing currently in dispute alters the fact that the industry groups agreed to a shift in the use of legal these terms which delivers a dramatic and probably irreversible expansion in the government's power to extract price reductions from companies with PBS-listed medicines. …
Why would it take these powers if it did not intend to use them?
September 28, 2022 Latest NewsBioPharmaComment
Latest Video
Georgia Forrest
New Stories
-
Telix files for European approval of brain cancer imaging candidate TLX101-Px
February 18, 2026 - - Australian Biotech -
IDT signals turnaround as revenue rises and losses narrow under strategic reset
February 18, 2026 - - Latest News -
Nyrada advances lead candidate into mid-stage trial as momentum builds across programs
February 18, 2026 - - Australian Biotech -
CSL and Lilly strike strategic deal to advance promising anti-inflammatory therapy
February 18, 2026 - - Latest News -
Targeted blood cancer treatments proposed for funding in New Zealand
February 18, 2026 - - Latest News -
Percheron targets next wave of immunotherapy with novel VISTA checkpoint candidate
February 18, 2026 - - Australian Biotech -
Urgent action needed as antibiotic resistance threatens Australia’s health future
February 17, 2026 - - Latest News